Xencor (NASDAQ:XNCR) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Wednesday.
A number of other research firms have also recently weighed in on XNCR. Cantor Fitzgerald initiated coverage on Xencor in a report on Wednesday, November 29th. They set an “overweight” rating and a $33.00 price target on the stock. ValuEngine cut Xencor from a “hold” rating to a “sell” rating in a report on Monday, October 23rd. Zacks Investment Research reaffirmed a “sell” rating on shares of Xencor in a report on Saturday, January 13th. Canaccord Genuity set a $36.00 price target on Xencor and gave the company a “buy” rating in a report on Monday, October 23rd. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $35.00 price target on shares of Xencor in a report on Sunday, November 12th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $30.80.
Xencor (NASDAQ:XNCR) traded down $0.61 on Wednesday, hitting $23.36. The stock had a trading volume of 74,533 shares, compared to its average volume of 135,111. The company has a market capitalization of $1,125.65, a PE ratio of -23.36 and a beta of 2.09. Xencor has a 52 week low of $18.55 and a 52 week high of $28.64.
In other news, major shareholder John S. Stafford III bought 13,700 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The shares were purchased at an average price of $19.81 per share, with a total value of $271,397.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder John S. Stafford III bought 50,000 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The shares were purchased at an average cost of $19.58 per share, for a total transaction of $979,000.00. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 103,882 shares of company stock worth $2,062,130. 4.03% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in XNCR. Great West Life Assurance Co. Can grew its position in Xencor by 158.9% in the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 4,005 shares during the last quarter. Legal & General Group Plc grew its position in Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 385 shares during the last quarter. Principal Financial Group Inc. acquired a new position in Xencor in the third quarter worth approximately $201,000. Citadel Advisors LLC acquired a new position in Xencor in the second quarter worth approximately $224,000. Finally, Voya Investment Management LLC grew its position in Xencor by 25.4% in the second quarter. Voya Investment Management LLC now owns 16,793 shares of the biopharmaceutical company’s stock worth $355,000 after buying an additional 3,405 shares during the last quarter. 77.50% of the stock is currently owned by hedge funds and other institutional investors.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.